Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes

Abstract

Exenatide and insulin glargine achieved similar improvements in overall glycemic control in patients with type 2 diabetes that was suboptimally controlled with oral combination therapy. Exenatide was associated with weight reduction and had a higher incidence of gastrointestinal adverse effects than insulin glargine.